UekiYMiuraTMiyashitaY. et al. Inflammatory cytokine levels after endovascular therapy in patients with peripheral artery disease. Angiology. 2016. pii: 0003319716682122.
2.
LavetiDKumarMHemalathaR. et al. Anti-inflammatory treatments for chronic diseases: a review. Inflamm Allergy Drug Targets. 2013;12(5):349–361.
3.
AraújoPVRibeiroMSDalioMB. et al. Interleukins and inflammatory markers in in-stent restenosis after femoral percutaneous transluminal angioplasty. Ann Vasc Surg. 2015;29(4):731–737.
4.
WangXBaoWLiuJ. et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36(1):166–175.
5.
Al-ShukailiAAL-GhafriSAl-MarhoobiS. et al. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol. 2013;2013:976810.
6.
Rodríguez-HernándezHSimental-MendíaLERodríguez-RamírezGReyes-RomeroMA. Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol. 2013;2013:678159.
7.
KornowskiRHongMKTioFOBramwellO. et al. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31(1):224–230.
8.
AngioiMAbdelmouttalebIRodriguezRM. et al. Increased C-reactive protein levels in patients with in-stent restenosis and its implications. Am J Cardiol. 2001;87(10):1189–1193.
9.
IkedaUShimadaK. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21(6):1090–1091.
10.
WeltFGRogersC. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22(11):1769–1776.
11.
BuDXGriffinGLichtmanAH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol. 2011;22(3):165–170.
12.
LeferDJ. Statins as potent antiinflammatory drugs. Circulation. 2002;106(16):2041–2042.
13.
JainMKRidkerPM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977–987.
